1ml tirzepatide Flex-Dose 1 mL Injectable 10 mg/mL 1ml tirzepatide GLP-2 TZ –

Tirzepatide-Specific Safety Considerations GI symptoms are generally mild to moderate Risk of hypoglycemia when used with insulin or sulfonylureas Rare risk of pancreatitis (class effect) Possible thyroid C-cell effects (class warning) Heart rate increases have been documented, but are generally modest Retatrutide-Specific Safety Considerations Higher overall rate of side effects compared to tirzepatide in Phase 2 data More pronounced heart rate increase this is a dose-dependent effect directly related to glucagon receptor activation (glucagon is known to increase heart rate in pharmacological doses) At 12 mg doses, some participants experienced increases in heart rate of 46 bpm above baseline

Pickart L

Always consult a licensed medical provider before beginning any GLP-1 program.

Therefore, in this study we addressed whether BPC 157 could activate the Src-Cav-1-eNOS signal pathway

What Can PBMs Do